Clinical Report: Stimulating Antitumor Immunity in Patients with Multiple Chronic Conditions

Background

The increasing global burden of cancer, particularly among older adults with multimorbidity, necessitates a shift in oncology from aggressive tumor treatment to a more holistic approach. Many cancer patients experience significant comorbidities that complicate treatment and reduce quality of life.

Data Highlights

No numerical data or trial results were provided in the source material.

Key Findings

• Many tumors in older adults are immunologically 'cold' with limited immune cell infiltration.
• Cryoablation can induce immunogenic cell death and promote dendritic-cell maturation.
• Traditional Chinese Medicine may reduce inflammatory signaling and remodulate the tumor microenvironment.
• The proposed Tumour Green Therapy framework includes three phases: Dominant Control, Supportive Integration, and Harmonisation and Maintenance.
• Combining cryoablation with TCM aims to lower treatment burden while maintaining quality of life.

Clinical Implications

This integrative approach emphasizes the need for individualized care. Clinicians should consider combining minimally invasive techniques with traditional therapies.

Conclusion

Further research is necessary to validate the proposed hypotheses and evaluate clinical outcomes.

Related Resources & Content

1. Frontiers in Immunology, 2026 -- Synergistic Immunomodulation: Integrating Physical Ablation with Immune Checkpoint Inhibitors for Metastatic Colorectal Carcinoma
2. The ASCO Post, 2019 -- The Future of Immunotherapy: Building on Checkpoint Blockade
3. The ASCO Post, 2019 -- In Era of Immunotherapy, Radiation Therapy May Become Essential Component of Systemic Treatments of Cancer
4. Geriatric Assessment: ASCO Global Guideline | JCO Global Oncology
5. Ablation plus immunotherapy versus immunotherapy alone in patients of advanced NSCLC who develop oligo-residual disease after anti-PD-1/L1 therapy (BOOSTER): a randomized phase 2 trial | Signal Transduction and Targeted Therapy
6. jadpro — CAR T-Cell Therapy Unveiled: Navigating Beyond CRS and ICANS to Address Delayed Complications and Optimize Management Strategies
7. Synthesis and Educational Overview of the ASCO–Society of Integrative Oncology Guidelines: On the Path to Implementation
8. Geriatric Assessment: ASCO Global Guideline | JCO Global Oncology
9. Ablation plus immunotherapy versus immunotherapy alone in patients of advanced NSCLC who develop oligo-residual disease after anti-PD-1/L1 therapy (BOOSTER): a randomized phase 2 trial | Signal Transduction and Targeted Therapy